300006.SZ
Chongqing Lummy Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 5.09
−3.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 759.5M | 775.7M | 795.6M | 895.6M | 884.6M |
| Cost of Revenue | 339.4M | 343.1M | 283.3M | 274.7M | 234.4M |
| Gross Profit | 420.1M | 432.6M | 512.3M | 620.9M | 650.1M |
| Operating Expenses | |||||
| R&D Expense | 58.3M | 62.5M | 64.7M | 99.8M | 80.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 131.0M | 134.6M | 139.2M | 139.4M | 131.8M |
| Selling & Marketing Expense | 301.2M | 309.3M | 396.7M | 462.0M | 530.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 496.0M | 510.2M | 599.8M | 698.0M | 764.4M |
| Cost and Expenses | 835.4M | 853.3M | 883.1M | 972.7M | 998.8M |
| Operating Income (EBIT) | (148.0M) | (146.2M) | (105.8M) | 56.2M | (96.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (148.7M) | (146.8M) | (75.5M) | 3.6M | (75.2M) |
| Income Tax Expense | (22.5M) | (20.3M) | 4.6M | 13.6M | 1.0M |
| Bottom Line | |||||
| Net Income | (135.9M) | (134.7M) | (87.8M) | (8.9M) | (68.7M) |
| Earnings from Cont. Ops | (126.2M) | (126.5M) | (80.1M) | (10.0M) | (76.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (135.9M) | (134.7M) | (87.8M) | (8.9M) | (68.7M) |
| Per Share | |||||
| Basic EPS | (CN¥0.13) | (CN¥0.13) | (CN¥0.08) | (CN¥0.01) | (CN¥0.07) |
| Diluted EPS | (CN¥0.13) | (CN¥0.13) | (CN¥0.08) | (CN¥0.01) | (CN¥0.07) |
| Revenue Per Share | CN¥0.72 | CN¥0.73 | CN¥0.75 | CN¥0.85 | CN¥0.84 |
| Shares | |||||
| Basic Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| Diluted Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| Profitability Metrics | |||||
| EBITDA | — | (97.6M) | (54.2M) | 124.3M | (23.7M) |
| D&A | — | 48.5M | 51.6M | 68.1M | 72.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026